accountthe first half of the year. The drug that helps stop bleeding during surgery has to compete against King Pharmaceuticals' (NYSE: KG) But Bristol-Myers is basically buying ZymoGenetics for its pipeline. The companies are partners on pegylated-interferon...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Is This Drugmaker a Lavish Spender or a Bargain Hunter?
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account